Astellas Pharma (ALPMY) Earnings Date, Estimates & Call Transcripts $10.10 +0.19 (+1.92%) As of 05/2/2025 03:59 PM Eastern Add Compare Share Share Earnings Stock AnalysisChartEarningsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock Astellas Pharma Earnings Summary Latest Q4 2025 Earnings DateApr. 25EstimatedConsensus EPS (Apr. 25) $0.15 Actual EPS (Apr. 25) $0.27 Beat By $0.12 Actual Revenue (Apr. 25) $3.22BAstellas Pharma released Q4 2025 earnings on April 25, 2025, reporting an EPS of $0.27, which topped the consensus estimate of $0.15 by $0.12. Quarterly revenue was reported to be $3.22 billion, above analysts' expectations of $3.02 billion. With a trailing EPS of $0.17, Astellas Pharma's earnings are expected to grow 61.90% next year, from $0.42 to $0.68 per share. Q4 2025 Earnings ResourcesQ4 2025 Earnings Report Get Astellas Pharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astellas Pharma and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataALPMY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALPMY Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Astellas Pharma Analyst EPS EstimatesCurrent Year EPS Consensus Estimate $0.42 EPSNext Year EPS Consensus Estimate $0.68 EPS Astellas Pharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails4/25/2025Q4 2025$0.1474$0.27+$0.1226$0.27$3.02B$3.22B2/4/2025Q3 2025-$0.30+$0.30-$0.36--10/30/2024Q2 2025-$0.13+$0.13$0.13-$3.11B8/1/2024Q1 2025-$0.24+$0.24$0.35-$3.03B4/25/2024Q4 2024-$0.11+$0.11$0.34-$2.79B2/5/2024Q3 2024-$0.12+$0.12$0.17-$2.86B11/1/2023Q3 2023$0.17-$0.01 -$0.18-$0.01-$2.71B8/1/2023Q2 2023$0.22$0.13 -$0.09$0.13-$2.73B Astellas Pharma Earnings - Frequently Asked Questions When did Astellas Pharma announce their last quarterly earnings? Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earning data on Friday, April 25, 2025. Learn more on ALPMY's earnings history. Did Astellas Pharma beat their earnings estimates last quarter? In the previous quarter, Astellas Pharma (OTCMKTS:ALPMY) reported $0.27 earnings per share (EPS) to beat the analysts' consensus estimate of $0.15 by $0.12. Learn more on analysts' earnings estimate vs. ALPMY's actual earnings. How much revenue does Astellas Pharma generate each year? Astellas Pharma (OTCMKTS:ALPMY) has a recorded annual revenue of $11.11 billion. How much profit does Astellas Pharma generate each year? Astellas Pharma (OTCMKTS:ALPMY) has a recorded net income of $113 million. ALPMY has generated $0.17 earnings per share over the last four quarters. What is Astellas Pharma's EPS forecast for next year? Astellas Pharma's earnings are expected to grow from $0.42 per share to $0.68 per share in the next year, which is a 61.90% increase. More Earnings Resources from MarketBeat Related Companies ZTS Earnings Date REGN Earnings Date DSNKY Earnings Date TAK Earnings Date ALNY Earnings Date BAYRY Earnings Date ONC Earnings Date MKKGY Earnings Date RPRX Earnings Date SMMT Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernVisa Q2 Earnings Top Forecasts, Adds $30B Buyback PlanMicrosoft Crushes Earnings, What’s Next for MSFT Stock?Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay AwayAMD Stock Signals Strong Buy Ahead of Earnings This page (OTCMKTS:ALPMY) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredU.S. Stock Market Now on Verge of CollapseThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
